Want to see IMRX full AI Analyst Report?
Immuneering (IMRX) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Atebimetinib, Gnp, Mgnp | Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (Pdac), Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pdac, Pancreatic Cancer Metastatic, Pdac - Pancreatic Ductal Adenocarcinoma | Phase III | Recruiting | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Apr 20, 2026 | ― |
| Imm-6-415 | Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Advanced Solid Tumor (Phase 1), Malignant Melanoma (Cutaneous) | phase1AndPhase2 | Completed | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | Jan 05, 2024 | ― |
| Imm-1-104 Monotherapy, Imm-1-104 + Modified Gemcitabine/Nab-Paclitaxel, Imm-1-104 + Modified Folfirinox, Imm-1-104 + Dabrafenib, Imm-1-104 + Pembrolizumab | Advanced Solid Tumor, Non-Small Cell Lung Cancer (Nsclc), Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous) | phase1AndPhase2 | Active Not Recruiting | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | Oct 14, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Atebimetinib, Gnp, Mgnp | Phase III | Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (Pdac), Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pdac, Pancreatic Cancer Metastatic, Pdac - Pancreatic Ductal Adenocarcinoma | Recruiting | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Apr 20, 2026 | ― |
| Imm-6-415 | phase1AndPhase2 | Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Advanced Solid Tumor (Phase 1), Malignant Melanoma (Cutaneous) | Completed | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | Jan 05, 2024 | ― |
| Imm-1-104 Monotherapy, Imm-1-104 + Modified Gemcitabine/Nab-Paclitaxel, Imm-1-104 + Modified Folfirinox, Imm-1-104 + Dabrafenib, Imm-1-104 + Pembrolizumab | phase1AndPhase2 | Advanced Solid Tumor, Non-Small Cell Lung Cancer (Nsclc), Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous) | Active Not Recruiting | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | Oct 14, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Immuneering Corp. Class A (IMRX) have in its pipeline
Immuneering IMRX is currently developing the following drugs: Atebimetinib, Gnp, Mgnp, Imm-6-415, Imm-1-104 Monotherapy, Imm-1-104 + Modified Gemcitabine/Nab-Paclitaxel, Imm-1-104 + Modified Folfirinox, Imm-1-104 + Dabrafenib, Imm-1-104 + Pembrolizumab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.